X

Trial Profile

Phase I study of a DNA-based vaccine targeting prostatic acid phosphatase (PAP) in patients with stage D0 prostate cancer.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MVI 816 (Primary) ; Granulocyte macrophage colony stimulating factor
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Pharmacodynamics

Most Recent Events

27 Sep 2010 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
19 Apr 2009 Status changed from active, no longer recruiting to completed, as reported in bstract number 729 presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR), held in Denver, Colorado, USA in April 2009.
18 Apr 2009 Primary outcome amended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com